Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

BioLineRx Ltd (BLRX)

NASDAQ
Symbol
Exchange
Currency
BLRXNASDAQUSD
BLRXTel AvivILS
Currency in USD
Disclaimer
0.592
-0.021(-3.39%)
Real-time Data

BLRX Comments

💵🧨🚀
https://www.tipranks.com/stocks/blrx/forecast
This stock will be $20+ this year. Don’t worry guys. We have plenty of time for this to run up. Just let the market do it’s job. We will be rewarded in time ! Stay long and enjoy the ride
Well, if upcoming P3 result is as good, better or even close to what we thought after DSMC recommendation, the stock will easily cross 20$ in my opinion.
Apart from the SCM treatment for Multiple Myeloma being approved in 4Q21(>95% probability IMO), I also think BLRX will announce a lucrative partnership with Merck for their current Ph II pancreatic cancer trial to improve efficacy of Keytruda. There could be significant milestone payments, as well as licensing/royalty agreements. And then there are other potential positive drivers for the solid tumor study (AGI-134) and for ARDS. My target is still $25 by Christmas (accounting for some dilution in the teens) and $50 by 2022 - unless they are bought out earlier by big Pharma.
Look at nasdaq the target price fromhc is 22$They work closely with Novartis and Merck
Outperform rating by analyst. expected price target end of year - $12 Awaiting Phase 3 results - stem cell mobilization for myeloma (blood cancer) - Great buying opp
So if this company maxes out at 33 mil American shares. This can be$ 20 or so. Wow! I understand how someone can get confused!! That is much better!!
BLRX what you need baby, some water? So pls start to fly!
From a couple of hours ago: H.C. Wxinwxxxht analyst Josxxh Pxxxginis raised the firm's price target on BioLineRx to $22 as he increased his projected odds of success for stem cell mobilization to 90% from 40% and raised his projected odds of success for pancreatic cancer to 60% from 30% after the company announced data from its COMBAT study in Stage IV pancreatic cancer. The analyst, who calls the data "a far cry from the very broad graveyard of failures in the pancreatic arena," noted that the COMBAT results showed improvements across all endpoints. The selloff in the shares following the report "is a classic example of 'sell on the news' following a strong stock run up," added Pantginis, who keeps a Buy rating on BioLineRx shares. I bought more...
Biolin target price 22-30$ Dollars, one of the best pharma stock under radar
Why is this taking off this morning? Up 38% before 5am EST.
Target price is 22$ in 2-3 weeks there will be a big move
Green tomorrow ?
What's going guys? Is this a good stock to buy?
yes this is a good choice
Yes this is a good choice
all in (almost) because phase 3 trial..
2.26
if closed above $2.5 then next day opening $3
Volume is off the chart today
That really looked like a reversal??? 2.77 going to be tuff to breach. Good Luck
.5 cents at a time!!!
they announce positive result!!! I think it will go to 4!! : ) coming soon!
Welp, I'd of thought that this morning but 3 is all we got. I'm going to hold on for close....hope you are right!! Good Luck
afternoon runner
Technical pont $4-6 within 4-6 weeks? In @ $1.62, sold 1/3 @ $2.70.  Rebuy if drops to 2.30 and selling a 3.95 and again @ 4.70.  watch RSI and Fibonacci.
lets go to 4
You think? I'm feeling like the run is done
perhaps after lunch.....
whats that
I'm in 2.17
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.